CRISPR Therapeutics AG (CRISPR Therapeutics AG) Debt-to-EBITDA : 0.80 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CRISPR Therapeutics AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.6 Mil. CRISPR Therapeutics AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $223.0 Mil. CRISPR Therapeutics AG's annualized EBITDA for the quarter that ended in Dec. 2023 was $297.9 Mil. CRISPR Therapeutics AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CRISPR Therapeutics AG's Debt-to-EBITDA or its related term are showing as below:

CRSP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.5 Med: -0.28 Max: 1.02
Current: -1.18

During the past 10 years, the highest Debt-to-EBITDA Ratio of CRISPR Therapeutics AG was 1.02. The lowest was -1.50. And the median was -0.28.

CRSP's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs CRSP: -1.18

CRISPR Therapeutics AG Debt-to-EBITDA Historical Data

The historical data trend for CRISPR Therapeutics AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Debt-to-EBITDA Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

1.02

-0.18

0.58

-0.38

-1.18

CRISPR Therapeutics AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.49	-1.01	-0.68	-0.47	0.80

Competitive Comparison of CRISPR Therapeutics AG's Debt-to-EBITDA

For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-EBITDA falls into.

CRISPR Therapeutics AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CRISPR Therapeutics AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(15.625	+	223.007)	/	-202.701
	=	-1.18

CRISPR Therapeutics AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(15.625	+	223.007)	/	297.932
	=	0.80

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

CRISPR Therapeutics AG (NAS:CRSP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CRISPR Therapeutics AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Executives

Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104